盐酸扎利罗登
盐酸扎利罗登结构式
|
常用名 | 盐酸扎利罗登 | 英文名 | Xaliproden hydrochloride |
|---|---|---|---|---|
| CAS号 | 90494-79-4 | 分子量 | 417.89400 | |
| 密度 | N/A | 沸点 | 487.8ºC at 760mmHg | |
| 分子式 | C24H23ClF3N | 熔点 | N/A | |
| MSDS | 美版 | 闪点 | 248.8ºC | |
| 符号 |
GHS07 |
信号词 | Warning |
|
5-HT1A receptors are involved in the effects of xaliproden on G-protein activation, neurotransmitter release and nociception.
Br. J. Pharmacol. 158(1) , 232-42, (2009) Xaliproden (SR57746A) is a 5-HT(1A) receptor agonist and neurotrophic agent that reduces oxaliplatin-mediated neuropathy in clinical trials. The present study investigated its profile on in vitro transduction, neurochemical responses and acute nociceptive pai... |
|
|
Magnetic resonance imaging of the neuroprotective effect of xaliproden in rats.
Invest. Radiol. 37(6) , 321-7, (2002) The neurotrophic effect of Xaliproden has been followed using sequential cerebral magnetic resonance imaging (MRI) in rats with vincristine-induced brain lesion as a model of Alzheimer disease.Nineteen rats received an intraseptal injection of vincristine on ... |
|
|
The neuroprotective agent SR 57746A abrogates experimental autoimmune encephalomyelitis and impairs associated blood-brain barrier disruption: implications for multiple sclerosis treatment.
Proc. Natl. Acad. Sci. U. S. A. 96(22) , 12855-9, (1999) Experimental autoimmune encephalomyelitis (EAE) is a T cell autoimmune disorder that is a widely used animal model for multiple sclerosis (MS) and, as in MS, clinical signs of EAE are associated with blood-brain barrier (BBB) disruption. SR 57746A, a nonpepti... |
|
|
SR57746A: a survival factor for motor neurons in vivo.
J. Neurol. Sci. 160 Suppl 1 , S92-6, (1998) SR57746A(1-[2-(naphth-2-yl)ethy]]-4-(3-trifluoromethyl phenyl)-1,2,5,6-tetrahydropyridine, hydrochloride) is a non-peptide compound which has been shown to exhibit a wide range of neurotrophic effects both in vitro and in vivo. Here we examine the ability of ... |
|
|
Administration of amyloid beta-peptides in the rat medial septum causes memory deficits: reversal by SR 57746A, a non-peptide neurotrophic compound.
Neurosci. Lett. 213(2) , 79-82, (1996) Different putative toxic amyloid beta (A beta) peptides, beta (1-42), beta (1-40) and beta (25-35), were infused (0.75, 1.5 or 3 nmol) in the rat medial septum. Memory deficits were then investigated using the social recognition test. A significant amnesia wa... |
|
|
The non-peptide neuroprotective agents SR 57746A interacts with neurotrophin 3 to induce differentiation in the PC12 cell-line.
J. Pharm. Pharmacol. 50(3) , 323-7, (1998) SR 57746A (1-(2beta-naphthylethyl)-4-(3-trifluoromethylphenyl)-1,2,5,6 -tetrahydropyridine hydrochloride) is a neuroprotective compound which potentiates nerve-growth factor (NGF)-induced differentiation in PC12 cells. We have evaluated the interaction of SR ... |
|
|
Inhibition of lysophosphatidic acid-induced neurite retraction and cell rounding by SR 57746A.
Brain Res. Mol. Brain Res. 53(1-2) , 301-6, (1998) Rapid neurite retraction and transient rounding of serum-starved NG108-15 and PC12 cells by lysophosphatidic acid (LPA) is retarded and reduced by pre-incubation of the cells with the small non-peptidic molecule, SR 57746A, which exhibits neurotrophic propert... |
|
|
SR 57746A attenuates cytostatic drug-induced reduction of neurite outgrowth in co-cultures of rat dorsal root ganglia and Schwann cells.
Neurosci. Lett. 203(1) , 9-12, (1996) A co-culture system of intact rat dorsal root ganglia (DRG) with Schwann cells was used to evaluate the potential neurotrophic activity of SR 57746A. Neuritogenesis from DRG was measured with an image analysis system following exposure to different concentrat... |
|
|
SR 57746A/xaliproden, a non-peptide neurotrophic compound: prospects and constraints for the treatment of nervous system diseases.
Expert Opin. Investig. Drugs 18(11) , 1765-72, (2009) Neurodegenerative disorders such as Alzheimer's disease or amyotrophic lateral sclerosis as well as peripheral neuropathies are difficult to treat due to a limited range of effective drugs. Neurotrophic growth factors promote neuronal survival and differentia... |
|
|
What we have learned from the Xaliproden Sanofi-aventis trials.
J. Nutr. Health Aging 13(4) , 365-6, (2009)
|